|
|
Position:
Scientist - Discovery Bioanalysis
Employer:
Genentech
Description:
The individual will be involved in the following activities as part of their role:
- Implement new technology platforms and novel tools for bioanalytical related DMPK challenges; maintain current knowledge of latest bioanalytical methods and technologies
- Developing highly sensitive and specific bioanalytical methods for quantitative analysis to support new modality drug discovery
- Expanding bioanalysis capability such as automation and improving study/process workflow
- Oversee discovery bioanalytical activities conducted at contract research laboratories (CROs), including study tracking and data review
- Participate and present in cross-functional project teams, manage multiple projects within timelines according to high scientific and ethical standards.
Qualifications/Experience:
The candidate for the DMPK-Bioanalytical Scientist position must have a doctoral degree in analytical chemistry, biochemistry, pharmaceutical science with 0-3 years relevant industry experience.
- Experience in biological sample extraction such as SLE, LLE, SPE and PP is required.
- Experience with LC-MS/MS quantitation is required.
- Experience with high resolution MS such as QTOF or Orbitrap is required.
- Experience in LC-MS analysis of small molecules is preferred
- Experience in LC-MS analysis of peptides, ADC, nucleic acids, proteins or glycans is a plus.
- The ability to assist in troubleshooting with instrument or assay problems arise is required.
The candidate needs to possess a demonstrated ability to work independently in a fast-paced environment, as well as in a team setting. A basic understanding of pharmacokinetics or drug metabolism would be preferred. The candidate should have excellent oral and written communication skills.
Location:
South San Francisco
Contact:
Nancy Zhang (zhanx239@gene.com)
Post Date:
8/25/2022 12:57:12 PM
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Submit a Text Ad
|